THERAPY DOSSIER · th-a21198443163

Human umbilical cord blood-derived neural stem cells (HUCB-NSC) with immunosuppression

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23595286 ↗2013No effect reported

Different methods of immunosuppresion do not prolong the survival of human cord blood-derived neural stem cells transplanted into focal brain-injured immunocompetent rats.

RatChemical/toxinWistarMaleCyclosporine A and azathioprine intraperitoneal, methylprednisolone intramuscular; cells transplanted into the brainCyclosporine A 10 mg/kg; azathioprine 5 mg/kg; methylpredni…

Model: Focal brain injury with cerebral infarct in immunocompetent rats, produced using ouabain

Transplanted cell numbers fell gradually with complete disappearance by day 14 in all groups and no difference between immunosuppressive regimes; the innate immune response dominated and peaked at day 3.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…